The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Recruiting in Palo Alto (17 mi)

+419 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Eli Lilly and Company

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.

Research Team

Eligibility Criteria

Inclusion Criteria

Adult patients with severe sepsis.

Presence of a suspected or proven infection.

One or more sepsis-associated organ failure.

Treatment Details

Interventions

Drotrecogin Alfa (Activated) (Protein C Activator)

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.Gainesville, FL

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.Tamarac, FL

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.Jackson, MS

More Trial Locations

Loading ...